Expanded autologous regulatory T-lymphocyte infusions in ALS: A phase I, first-in-human study

Conclusions These results demonstrate the safety and potential benefit of expanded autologous Treg infusions, warranting further clinical trials in patients with ALS. The correlation between Treg suppressive function and disease progression underscores the significance of using Treg suppressive function as an indicator of clinical status. Classification of evidence This study provides Class IV evidence. This is a phase I trial with no controls.

http://nn.neurology.org/cgi/content/short/5/4/e465?rss=1

Source: Neurology Neuroimmunology and Neuroinflammation - May 18, 2018 Category: Neurology Authors: Thonhoff, J. R., Beers, D. R., Zhao, W., Pleitez, M., Simpson, E. P., Berry, J. D., Cudkowicz, M. E., Appel, S. H. Tags: All Immunology, Amyotrophic lateral sclerosis, All Clinical trials, Class IV Article Source Type: research